Oxycodone (Oxycontin, Roxicodone, Xtampza) — 2026 Medicare Part D coverage
oxycodone — sold as Oxycontin, Roxicodone, Xtampza: 26 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover oxycodone?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| oxyCODONE HCl 10 MG Oral Tablet generic · RxCUI 1049683 | 326 (99%) | 3 | 3 | 0 | 293 |
| oxyCODONE HCl 15 MG Oral Tablet generic · RxCUI 1049611 | 326 (99%) | 3 | 3 | 0 | 293 |
| oxyCODONE HCl 20 MG Oral Tablet generic · RxCUI 1049686 | 326 (99%) | 3 | 3 | 0 | 293 |
| oxyCODONE HCl 30 MG Oral Tablet generic · RxCUI 1049618 | 326 (99%) | 3 | 4 | 0 | 290 |
| oxyCODONE HCl 5 MG Oral Tablet generic · RxCUI 1049621 | 326 (99%) | 3 | 3 | 0 | 293 |
| oxyCODONE HCl 5 MG in 5 mL Oral Solution generic · RxCUI 1049604 | 231 (70%) | 4 | 0 | 0 | 197 |
| oxyCODONE HCl 20 MG in 1 mL Concentrate for Oral Solution generic · RxCUI 1049615 | 162 (49%) | 4 | 10 | 0 | 151 |
| oxyCODONE HCl 5 MG Oral Capsule generic · RxCUI 1049696 | 120 (37%) | 2 | 3 | 0 | 111 |
| OxyCONTIN 10 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049504 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 15 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049545 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 20 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049565 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 30 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049576 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 40 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049586 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 60 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049595 | 51 (16%) | 1 | 30 | 0 | 50 |
| OxyCONTIN 80 MG 12HR Extended Release Oral Tablet brand · RxCUI 1049601 | 51 (16%) | 1 | 30 | 0 | 50 |
| Xtampza ER 13.5 MG 12HR Extended Release Oral Capsule brand · RxCUI 1791560 | 26 (8%) | 3 | 3 | 0 | 8 |
| Xtampza ER 18 MG 12HR Extended Release Oral Capsule brand · RxCUI 1791569 | 26 (8%) | 3 | 3 | 0 | 8 |
| Xtampza ER 27 MG 12HR Extended Release Oral Capsule brand · RxCUI 1791576 | 26 (8%) | 3 | 3 | 0 | 8 |
| Xtampza ER 36 MG 12HR Extended Release Oral Capsule brand · RxCUI 1791582 | 26 (8%) | 3 | 3 | 0 | 8 |
| Xtampza ER 9 MG 12HR Extended Release Oral Capsule brand · RxCUI 1790533 | 26 (8%) | 3 | 3 | 0 | 8 |
| oxyCODONE hydrochloride 15 MG Oral Tablet, Abuse-Deterrent generic · RxCUI 1944529 | 20 (6%) | 2 | 0 | 0 | 18 |
| oxyCODONE hydrochloride 10 MG Oral Tablet, Abuse-Deterrent generic · RxCUI 2693194 | 6 (2%) | 3 | 0 | 0 | 6 |
| oxyCODONE hydrochloride 30 MG Oral Tablet, Abuse-Deterrent generic · RxCUI 1944538 | 6 (2%) | 3 | 0 | 0 | 6 |
| oxyCODONE hydrochloride 5 MG Oral Tablet, Abuse-Deterrent generic · RxCUI 1944541 | 6 (2%) | 3 | 0 | 0 | 6 |
| ROXICODONE 15 MG Oral Tablet brand · RxCUI 1049613 | 1 (0%) | 1 | 0 | 0 | 1 |
| ROXICODONE 30 MG Oral Tablet brand · RxCUI 1049620 | 1 (0%) | 1 | 0 | 0 | 1 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.